- Home
- IONS vs CYTK Comparison
IONS vs CYTK Comparison
Compare IONS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IONS
- CYTK
- Stock Information
- Founded
- IONS 1989
- CYTK 1997
- Country
- IONS United States
- CYTK United States
- Employees
- IONS N/A
- CYTK N/A
- Industry
- IONS Biotechnology: Pharmaceutical Preparations
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- IONS Health Care
- CYTK Health Care
- Exchange
- IONS Nasdaq
- CYTK Nasdaq
- Market Cap
- IONS 5.4B
- CYTK 5.6B
- IPO Year
- IONS 1991
- CYTK 2004
- Fundamental
- Price
- IONS $33.51
- CYTK $31.02
- Analyst Decision
- IONS Buy
- CYTK Buy
- Analyst Count
- IONS 18
- CYTK 15
- Target Price
- IONS $57.41
- CYTK $73.71
- AVG Volume (30 Days)
- IONS 1.5M
- CYTK 2.4M
- Earning Date
- IONS 04-30-2025
- CYTK 05-06-2025
- Dividend Yield
- IONS N/A
- CYTK N/A
- EPS Growth
- IONS N/A
- CYTK N/A
- EPS
- IONS N/A
- CYTK N/A
- Revenue
- IONS $717,253,000.00
- CYTK $19,218,000.00
- Revenue This Year
- IONS $7.14
- CYTK $24.01
- Revenue Next Year
- IONS $18.89
- CYTK $698.33
- P/E Ratio
- IONS N/A
- CYTK N/A
- Revenue Growth
- IONS N/A
- CYTK 412.21
- 52 Week Low
- IONS $23.95
- CYTK $29.31
- 52 Week High
- IONS $52.34
- CYTK $61.38
- Technical
- Relative Strength Index (RSI)
- IONS 56.80
- CYTK 39.05
- Support Level
- IONS $32.00
- CYTK $30.02
- Resistance Level
- IONS $33.65
- CYTK $31.27
- Average True Range (ATR)
- IONS 1.08
- CYTK 1.40
- MACD
- IONS -0.10
- CYTK 0.24
- Stochastic Oscillator
- IONS 55.72
- CYTK 42.12
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.